Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 434-441

  Ahmed, K A ^a   Stallworth, D G ^a   Kim, Y ^a   Johnstone, P A S ^a   Harrison, L B ^a   Caudell, J J ^a   Yu, H M ^a   Etame, A B ^a   Weber, J S ^b   Gibney, Geoffrey T ^c,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Anti PD 1 therapy; Melanoma; Nivolumab; Stereotactic radiation

Indexed keywords

B RAF KINASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACARBAZINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; IPILIMUMAB; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; NY ESO 1 ANTIGEN; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; STEROID; TEMOZOLOMIDE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INOPERABLE CANCER; KARNOFSKY PERFORMANCE STATUS; MALE; METASTATIC MELANOMA; NEUROTOXICITY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STEREOTACTIC RADIATION; STEREOTACTIC RADIOSURGERY; TREATMENT FAILURE; TUMOR VOLUME; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOSURGERY; SECONDARY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY; RETROSPECTIVE STUDIES;

EID: 84959919017     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv622     Document Type: Article

References (39)

1. Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res 2012; 22: 177-183.
2. Fife KM, Colman MH, Stevens GN et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-1300.
3. Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117: 1687-1696.
4. Yu C, Chen JC, Apuzzo ML et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002; 52: 1277-1287.
5. Ramakrishna N, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 2013; 399-403.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
7. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
8. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
9. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
10. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
11. Anker CJ, Ribas A, Grossmann AH et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31: e283-e287.
12. Boussemart L, Boivin C, Claveau J et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149: 855-857.
13. Schulze B, Meissner M, Wolter M et al. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 2014; 190: 229-232.
14. Gaudy-Marqueste C, Carron R, Delsanti C et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25: 2086-2091.
15. Ahmed KA, Freilich JM, Sloot S et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2015; 122: 121-126.
16. Narayana A, Mathew M, Tam M et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113: 411-416.
17. Mathew M, Tam M, Ott PA et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23: 191-195.
18. Kiess AP, Wolchok JD, Barker CA et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92: 368-375.
19. Knisely JP, Yu JB, Flanigan J et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117: 227-233.
20. Silk AW, Bassetti MF, West BT et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2: 899-906.
21. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31: 4311-4318.
22. Gibney GT, Kudchadkar RR, DeConti RC et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected highrisk metastatic melanoma. Clin Cancer Res 2015; 21: 712-720.
23. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
24. Shaw E, Scott C, Souhami L et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000; 47: 291-298.
25. Sun A, Bae K, Gore EM et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011; 29: 279-286.
26. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol 2004; 31: 702-713.
27. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491.
28. Minniti G, Clarke E, Lanzetta G et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011; 6: 48.
29. Sambade MJ, Peters EC, Thomas NE et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of BRAF with PLX-4032. Radiother Oncol 2011; 98: 394-399.
30. Harding JJ, Barker CA, Carvajal RD et al. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 2014; 32: e54-e56.
31. Radbill AE, Fiveash JF, Falkenberg ET et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004; 101: 825-833.
32. Gaudy-Marqueste C, Regis JM, Muracciole X et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 809-816.
33. Liew DN, Kano H, Kondziolka D et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011; 114: 769-779.
34. BerghoffAS, Ricken G, Widhalm G et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015; 66: 289-299.
35. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
36. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
37. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
38. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889-1894.
39. Margolin K, ErnstoffMS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.